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Abstract
Background: Studies showed that axillary lymph node dissection can be safely omitted in presence of positive
sentinel lymph node(s) in breast cancer patients treated with breast conserving therapy. Since the outcome of the
sentinel lymph node biopsy has no clinical consequence, the value of the procedure itself is being questioned. The
aim of the BOOG 2013–08 trial is to investigate whether the sentinel lymph node biopsy can be safely omitted in
clinically node negative breast cancer patients treated with breast conserving therapy.
Methods: The BOOG 2013–08 is a Dutch prospective non-inferiority randomized multicentre trial. Women with
pathologically confirmed clinically node negative T1–2 invasive breast cancer undergoing breast conserving therapy
will be randomized for sentinel lymph node biopsy versus no sentinel lymph node biopsy. Endpoints include
regional recurrence after 5 (primary endpoint) and 10 years of follow-up, distant-disease free and overall survival,
quality of life, morbidity and cost-effectiveness. Previous data indicate a 5-year regional recurrence free survival rate
of 99% for the control arm and 96% for the study arm. In combination with a non-inferiority limit of 5% and
probability of 0.8, this result in a sample size of 1.644 patients including a lost to follow-up rate of 10%. Primary and
secondary endpoints will be reported after 5 and 10 years of follow-up.
Discussion: If the sentinel lymph node biopsy can be safely omitted in clinically node negative breast cancer patients
undergoing breast conserving therapy, this study will cost-effectively lead to a decreased axillary morbidity rate and
thereby improved quality of life with non-inferior regional control, distant-disease free survival and overall survival.
Trial registration: The BOOG 2013–08 study is registered in ClinicalTrials.gov since October 20, 2014, Identifier:
NCT02271828. https://clinicaltrials.gov/ct2/show/NCT02271828
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Background
More than fifteen years ago, the sentinel lymph node bi-
opsy (SLNB) was introduced in clinically node negative
breast cancer patients to evaluate their lymph node sta-
tus for diagnostic purposes. In case of a negative sentinel
lymph node (SLN) an axillary lymph node dissection
(ALND) was omitted. The SLN is negative in approxi-
mately 74% of patients in a general breast cancer popu-
lation [1, 2]. Although SLNB is less invasive compared
to ALND, short-term complications still occur in 25% of
the patients. Most reported complications are axillary
seroma, wound infections, hematoma, anaphylactic reac-
tion, axillary paresthesia, and lymphedema, which is de-
scribed in 8% of patients after a follow-up of only
3 years, resulting in significant reduction of quality of
life (QoL) of breast cancer survivors [3–7].
Ever since the National Surgical Adjuvant Breast and
Bowel Project (NSABP B-04) trial, the need for comple-
tion axillary treatment for clinically node negative patients
has been questioned. This trial revealed that omitting
ALND in clinically node negative patients did not affect
disease-free survival (DFS) and overall survival (OS) [8].
Patients were randomized for mastectomy-only, mastec-
tomy with ALND or mastectomy with axillary radiother-
apy (RT). About 40% of the patients who underwent
mastectomy-only had lymph node metastases that were
not removed at the time of initial surgery. During follow-
up, ipsilateral lymph nodes became clinically apparent in
less than half of these patients (18.6%). Nevertheless, omit-
ting ALND in clinically node negative patients did not
affect DFS and OS, even after 25 years of follow-up and
without adjuvant RT or systemic therapy.
The more recent American College of Surgeons On-
cology Group (ACOSOG) Z0011 and International
Breast Cancer Study Group (IBCSG) 23–01 trials inves-
tigated whether completion ALND can be safely omitted
in patients with a metastasis in the SLN. The ACOSOG
Z0011 trial included patients with 1–2 macrometastatic
SLN(s) who were treated with breast conserving therapy
(BCT) [9]. The IBCSG 23–01 trial only included patients
with a micrometastasis in the SLN, but gave no restric-
tion on type of breast surgery [10]. Most patients were
treated with adjuvant systemic treatment (both 97%). Pa-
tients in these trials were randomized to completion
ALND or watchful waiting. Additional lymph node me-
tastases beyond the SLN were detected in 27% (ACO-
SOG Z0011) and 11% (IBCSG 23–01) in the ALND
groups [9, 10]. Despite the fact that nodal metastases
remained in situ in a considerable percentage of patients
in the ‘watchful waiting’ groups, omitting completion
ALND did not result in inferior regional recurrence (RR)
rates, DFS and OS after 5-years of follow-up. These
studies indicated that completion ALND can be safely
omitted in presence of positive SLN(s) in patients
treated with BCT and adjuvant systemic treatment. Since
the outcome of the SLNB has no clinical consequence,
the value of the SLNB itself is being questioned.
Clinically node negative status in the NSABP B-04,
ACOSOG Z0011 and IBCSG 23–01 trials was based on
negative physical examination of the axilla. Preoperative
nodal staging with physical examination has a low accur-
acy, with a sensitivity of only 32% [11–14]. In the
Netherlands, axillary ultrasound is part of standard pre-
operative axillary work-up. The sensitivity of axillary ultra-
sound (in combination with tissue sampling where
deemed necessary) is approximately 80% [15]. Further-
more, a negative axillary ultrasound excludes the presence
of four or more lymph node metastases, with a negative
predictive value of 93–96% in the general breast cancer
population [16–18]. Therefore, axillary ultrasound im-
proves preoperative selection of node negative patients, as
it selects patients with a more favourable tumour load and
confidently excludes advanced nodal disease.
Several factors besides surgery have proven to decrease
RR rates. For instance, it is assumed that biology plays an
important role in dormancy of nodal metastases. Less than
half of the patients with occult nodal metastases in the
NSABP B-04 trial, developed clinically detectable lymph
nodes during follow-up, none of these patients received ad-
juvant systemic or RT [8]. Adjuvant systemic therapy is
known to decrease RR rates [19]. Primary systemic therapy
can eradicate lymph node metastases with a reported
pathologic complete response rates of 20–40% [20–23].
Lack of knowledge on the pathological lymph node status
is nowadays hardly influencing systemic therapy indication
[24]. Low RR rates in the ACOSOG Z0011 (and IBCSG
23–01) trial might be due to whole breast irradiation (WBI)
following lumpectomy [25–28]. RT of the breast may con-
tribute to the elimination of (occult) lymph node metasta-
ses by including part of the axilla [25]. A recent study has
shown that, even with contemporary 3D radiation tech-
niques, the SLN receives an elective radiation dose in 76%
of patients [29]. Biology, adjuvant systemic and RT most
likely diminish the risk that possible lymph node metastases
left in situ develop into clinically detectable lymph nodes.
This randomized controlled BOOG 2013–08 trial pro-
poses to demonstrate that the SLNB can be safely omitted
in breast cancer patients with a clinically node negative
T1–2 status undergoing BCT. This trial aims to decrease
the number of breast cancer patients receiving an invasive
axillary procedure, to decrease the axillary morbidity rate,
thereby improving QoL and reducing the costs of SLNB
without affecting regional control and survival.
Main study objectives
Primary objective of this study is to investigate whether
watchful waiting (i.e. no SLNB) is not inferior in terms
of 5 and 10-year RR rate to the current axillary staging
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regimen in breast cancer patients with a clinically node
negative T1–2 status undergoing BCT. Secondary objec-
tives are distant-DFS, OS, local recurrence (LR) rate,
contralateral breast cancer, number of delayed axillary
treatment, adjuvant RT, QoL, axillary morbidity rate,
and cost-effectiveness after 5- and 10-years of follow-up.
Methods
Study design
The BOOG 2013–08 is a Dutch prospective non-
inferiority randomized controlled multicentre trial.
Women with pathologically confirmed unilateral clinically
node negative T1–2 invasive breast cancer undergoing
BCT are randomized to SLNB or watchful waiting (i.e. no
SLNB). Primary and secondary endpoints will be reported
after 5 and 10 years of follow-up. The BOOG 2013–08 is
a multicentre trial and will be performed in 35 participat-
ing centres (Table 1). This study design was based on the
BOOG 2013–07 trial of the same research group [30].
Study population
Women ≥18 years with pathologically confirmed clinic-
ally node negative T1–2 invasive breast cancer, treated
with BCT (lumpectomy and WBI) are eligible for inclu-
sion. Clinically node negative is defined as no signs of
axillary lymph node metastases, consisting of a negative
physical examination of the axilla and preoperative axil-
lary ultrasound (or negative cyto−/histopathology in case
of a suspicious axillary lymph node) [30].
Exclusion criteria are: metastatic disease; bilateral
breast cancer; history of invasive breast cancer; previous
surgical treatment or RT of the ipsilateral axilla (except
surgery for superficially skin lesions, such as naevi or
hidradenitis suppurativa); other prior malignancies, ex-
cept successfully treated malignancies >5 years before
inclusion, successfully treated basal cell and squamous
cell skin cancer, and carcinoma in situ of the ipsilateral,
contralateral breast or cervix; and pregnancy or lactation
[30]. Primary systemic therapy and breast reconstruc-
tions are no exclusion criteria.
Axillary ultrasound
In the Netherlands, axillary ultrasound is standard care
for preoperative nodal staging of breast cancer patients
[30]. The following criteria are used to identify axillary
lymph node metastases during an axillary ultrasound:
cortical thickening, long to short axis ratio of <2 (i.e.
round), effacement or replacement of the fatty hilum,
and/or nonhilar blood flow [30]. If cortical thickening is
>2.3 mm, fine-needle aspiration biopsy is performed
[31]. Further, the radiologist can make a subjective as-
sessment of cortical thickening during real-time imaging
[16, 32, 33]. When suspicious lymph nodes are observed
during an axillary ultrasound, fine-needle aspiration
cytology or core needle biopsy is recommended. If more
than one suspicious lymph node is present, the most
suspicious lymph node is sampled [30].
Breast conserving therapy
BCT is defined as lumpectomy followed by WBI. The
primary tumour size is determined during pathological
assessment. Immunohistochemical (IHC) staining is
used to determine the hormone receptor status and is
Table 1 Participating centres BOOG 2013–08 study
Name participating centre
1. Alrijne hospital, Alphen aan de Rijn and Leiden
2. Amphia hospital, Breda
3. Antonius hospital, Sneek
4. Bronovo hospital and Medical Centre Haaglanden, den Haag
5. Canisius-Wilhelmina hospital, Nijmegen
6. Catharina hospital, Eindhoven
7. Deventer hospital, Deventer
8. Diakonessenhuis, Utrecht
9. Flevoziekenhuis, Almere
10. Gelderse Vallei, Ede
11. Gelre hospital, Apeldoorn
12. Groene Hart hospital, Gouda
13. Haga hospital, den Haag
14. Isala Clinic, Zwolle
15. Isala Diaconessenhuis, Meppel
16. Jeroen Bosch hospital, den Bosch
17. Laurentius hospital, Roermond
18. Maastricht University Medical Centre, Maastricht
19. Martini hospital, Groningen
20. Maxima Medical Centre, Eindhoven and Veldhoven
21. Meander Medical Centre, Amersfoort
22. Medical Spectrum Twente, Enschede and Oldenzaal
23. Netherlands Cancer Institute – Antoni van Leeuwenhoek,
Amsterdam
24. Noordwest ZHG, Alkmaar
25. Radboud University Medical Centre, Nijmegen
26. Reinier de Graaf Groep, Delft
27. Rijnstate hospital, Arnhem
28. Rivierenland hospital, Tiel
29. Sint Antonius hospital, Utrecht and Nieuwegein
30. Sint Elisabeth hospital, Tilburg
31. Spaarne Gasthuis, Haarlem and Hoofddorp
32. University Medical Centre Groningen, Groningen
33. University Medical Centre Utrecht, Utrecht
34. Zuyderland hospital Sittard and Heerlen
35. Zuwehofpoort hospital, Woerden
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considered positive if ≥10% of the cells stain positive.
HER2neu status is determined by IHC, or in case of 2+
by Chromogenic In Situ Hybridization (CISH) or Fluor-
escence In Situ Hybridization (FISH) [30].
World Health Organization is used to define the histo-
logical tumour type. The modified Bloom-Richardson
grading system is used to assess histological tumour grad-
ing. Multifocality is defined as foci or carcinoma separate
from the primary breast tumor. Lymphovascular invasion
is defined as ≥1 tumour cells in a lymphatic or vascular
structure [30].
Sentinel lymph node biopsy
The SLN procedure is performed using technetium-99 m
Nanocolloid as a radioactive tracer and blue dye for
lymphatic mapping. Both are injected into breast paren-
chymal tissue surrounding the tumour, biopsy cavity or
periareolar. The SLN is identified using the following
triple technique: lymphoscintigraphy, intraoperative use of
the gamma probe, and intraoperative detection of the blue
lymphatic vessels. After removal of the SLN(s), palpation
of the axilla is performed to identify and remove add-
itional suspicious (non-) SLN(s) [30].
Each SLN is examined at three histological levels (500-
μm intervals) as a minimal requirement for pathological as-
sessment. Two parallel sections on each level are per-
formed, one for haematoxylin and eosin (H&E) staining
and one for IHC staining [30]. When H&E staining is nega-
tive IHC staining is done. Lymph nodes marked by the sur-
geon as non-SLNs are also examined with H&E and if
negative with cytokeratin IHC staining. The diameter of
each metastasis and the presence of extranodal growth
must be determined. Isolated tumour cells (<0.2 mm) are
considered as SLN negative [30].
Radiation therapy
Dose and fractionation for whole breast radiation
A fractionation scheme equivalent to 25 × 2 Gray (Gy),
5 fractions per week is applied. Most Dutch RT centers
use a scheme of 15–16 × 2.67 Gy, 5 fractions per week.
In case of focal irradical resection, a higher boost dose is
recommended (equivalent to 10–13 × 2 Gy) [30]. Partial
breast irradiation is not allowed.
Delineation of whole breast radiation
The European Society for Radiotherapy and Oncology
(ESTRO) guidelines of Offersen et al. are used to per-
form delineation of target volumes and organs at risk
[34]. Delineation of tumour bed, including a clinical tar-
get volume (CTV) and a planning target volume (PTV)
is obligatory. In addition, delineation of axillary nodal re-
gions, axilla level 1, 2, Rotter nodes and 3 is obligatory,
even when there is no indication for axillary radiation.
In case of left-sided breast cancer, delineation of the
heart and lungs is obligatory [30].
Radiation technique and dose distribution
The dose in the target volume (whole breast, with or with-
out axillary and periclavicular nodes irradiation) must be
between 95%–107% of the prescribed dose [30]. The Cen-
tral Lung Distance must be <3 cm (in case of tangential
fields) and mean lung dose should be <7.5 Gy. The Max-
imum Heart Distance (in case of tangential fields) must be
<1 cm, and the heart volume receiving >10 Gy should be
<15%. If lung or heart constraints cannot be met, some
underdose in the breast can be accepted to reach the con-
straints, provided that the PTV of the tumour bed is ad-
equately covered. Breath holding techniques to reduce
heart dose are highly recommended for left sided breast
cancer patients. For evaluation purposes, the minimum,
maximum and mean dose of the axilla level 1, 2, Rotter
nodes, and 3 must be recorded [30].
Consent and randomization
Eligible patients will be informed about the study aim,
randomization procedure, consequences of participating
(i.e. possible adverse events), and their rights and respon-
sibilities by the attending surgeon. Written informed con-
sent must be obtained and randomization will be
performed preoperatively. Patients will be randomized be-
tween SLNB (control arm) and no SLNB (study arm).
Patients will be stratified by: clinical tumour size (<3 cm
vs. ≥3 cm), grading (grade I-II vs. III), oestrogen receptor
status (positive vs. negative), HER2neu status (positive vs.
negative), age (≤50, 50 ≤ 75, >75 years), primary systemic
therapy (yes vs. no) and participating centre.
Systemic therapy
According to the Dutch breast cancer guideline and
multidisciplinary approach, indication for systemic ther-
apy is determined for each individual patient [30, 31].
Adjuvant! Online can be used to estimate the 10-years
breast cancer specific survival and the risk reduction by
systemic therapy, with or without knowledge of the
pathological nodal status. Validated gene expression pro-
filing can be used as an addition to clinicopathologic
characteristics, in case of doubt about the indication for
adjuvant systemic therapy based on the traditional prog-
nostic factors. Primary systemic therapy is allowed, if the
patient has a clinically node negative T1–2 status that is
amenable to BCT surgery pre-systemic therapy.
Follow-up
The first five years of follow-up consists of outpatient
clinic visits once yearly, including a physical examination
of the axilla and a full-field digital mammography
(FFDM). Year six to ten of follow-up, consists of a FFDM
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annually in patients aged ≤60 years or once every two
years in patients aged >60 years [30]. Additional diagnostic
imaging is only performed on indication. Axillary ultra-
sound is performed, in case of a clinical suspicion of axil-
lary lymph node metastases. Staging for distant metastatic
disease is performed, if an axillary lymph node metastasis
is confirmed (cyto−/histopathology) or in case of a clinical
suspicion of distant metastatic disease [30].
Quality of life
A Dutch version of two validated QoL questionnaires of
the European Organization for the Research and Treat-
ment of Cancer (EORTC QLQ-C30 and QLQ-BR 23)
are used to assess the QoL of breast cancer patients. To
assess the subjective morbidity the validated Lymph-
edema Functioning, Disability and Health questionnaire
(Lymph-ICF) is used. A validated short version of the
Spielberger State-Trait Anxiety Inventory (STAI-trait)
and Neuroticism Extraversion Openness Five Factor In-
ventory (NEO-FFI) is used to measure if anxiety and
personality traits influences the outcome of QoL [35–
38]. The combination of these questionnaires will pro-
vide information on the general and breast cancer spe-
cific QoL, subjective morbidity, and anxiety and
personality traits that might influence the outcome of
QoL [39]. The first QoL questionnaires are provided
pre-randomisation for baseline measurement, and the
following are provided post-randomization at six
months, and at 1, 2, 3, 5 and 10 years. Patients are eli-
gible for evaluation when at least the pre-randomisation
questionnaire and the subsequent questionnaire are
completed [30].
Adverse events
Any undesirable experience during the study, whether or
not considered related to the protocol treatment is de-
fined as an adverse events (AEs), including seroma, post-
operative haemorrhage, wound complication/infection,
lymphedema of the arm or chest wall, neuralgia, paraes-
thesia, decreased arm or shoulder motion, muscle weak-
ness of the arm or shoulder, and pain in the arm or
shoulder. NCI/CTCAE 4.0 grading criteria is used to
grade the severity of the AE into mild, moderate, or se-
vere, in combination with the degree of limitation in ac-
tivities of daily living [30].
An untoward medical occurrence or effect related to
protocol treatment that results in death, hospitalisation
or prolongation of existing inpatients hospitalisation, or
surgery is defined as a serious adverse event (SAE).
Protocol treatment is defined as BCT of the primary
tumour, WBI, SLNB or completion axillary treatment.
Any other operation or adjuvant treatment is not con-
sidered protocol treatment [30].
The local investigator of the participating centre is re-
sponsible for reporting the SAE to the central data
centre within 24 h. The principal investigators of the
study are responsible for SAE assessment and reporting
to the accredited medical ethics committee within
15 days. For fatal or life threatening cases, the term is
maximal 7 days for a preliminary report with another
8 days to completion the report. All SAEs will be
followed until they have abated, or until a stable situ-
ation has been reached. Depending on the event, follow-
up may require additional tests or medical procedures as
indicated and/or referral to the general physician or a
medical specialist [30].
Statistics
Endpoints
Primary endpoint of this study is RR rate after 5 and 10-
years of follow-up. Secondary endpoints are regional re-
currence free survival (RRFS), number of delayed axillary
treatment, distant-DFS, OS, LR rate, other-RR rate,
contralateral breast cancer rate, diagnosis of recurrence
outside the axillary region, percentage difference in the
administration of postoperative RT, axillary morbidity rate,
QoL and cost-effectiveness after 5- and 10-years of follow-
up. RR, other-RR, LR and distant recurrence are defined
according the Maastricht Delphi Consensus on Event Def-
inition by Moossdorff et al. [40, 41]. Pathological confirm-
ation of a RR is mandatory. All suspected lesions for
recurrence on imaging, which are not accessible for hist-
ology or cytology, are presented to the Data Safety Moni-
toring Board (DSMB) for an independent review.
Time to event endpoints are defined as the time inter-
val between the date of randomization and the date of
first suspicion of the predefined recurrence, or the date
of death, whichever comes first, measured in days. Pa-
tients in whom recurrence is not observed and are still
alive are censored at the date of last follow-up. Death
from breast cancer and its treatment, death from a sec-
ond primary invasive non-breast cancer, and death from
other- or an unknown cause are recorded [30].
Administration of (neo) adjuvant systemic therapy is
registered and the percentage difference between both
study arms is recorded. Axillary morbidity rate is assessed
using a validated questionnaire and by predefined AE that
are recorded by the treating physician. QoL is assessed
using validated questionnaires. Cost-effectiveness is
assessed using the EQ-5D health questionnaire [30].
Sample size
Previous data indicate a 5-year regional recurrence free
survival rate of 99% for the control arm and 96% for the
study arm. The expected regional recurrence free sur-
vival rate and non-inferiority limit of 5% (delta) with a
probability of 0.8, result in a sample size of 747 per arm.
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When taking in account a lost to follow-up rate of 10%,
1.644 patients need to be randomized. An annual accrual
of 856 patients can be achieved, when taking into con-
sideration the incidence of women diagnosed with inva-
sive breast cancer in the Netherlands, the rate of
patients that is primarily operated (when excluding pa-
tients treated systemic therapy only, or patients with
metastatic disease and frail elderly), treatment with BCT,
the 35 participating hospitals, and an expected accrual
rate of 30%. Therefore, two years will suffice to include
the 1.644 patients.
Data safety monitoring board
An independent DSMB is established comprising an inde-
pendent surgeon, medical oncologist, radiation oncologist
and a statistician [30]. The independent DSMB will meet
annually to discuss RR, other events, occurrence of AEs,
and the percentage difference in administration of adju-
vant systemic therapy between both study arms [30]. The
DSMB can decide to alter the frequency of discussion. All
suspected lesions for recurrence on imaging, which are
not accessible for histology or cytology, are presented to
the Data Safety Monitoring Board (DSMB) for an inde-
pendent review. An interim analysis is performed by a
statistician, results will be presented to the DSMB for fur-
ther interpretation. The principal investigators will receive
the DSMB recommendations. Should the principle inves-
tigators decide not to fully implement the DSMB recom-
mendations, then the principle investigators have to send
the recommendation to the accredited medical ethics
committee, including a note to substantiate why (part of)
this recommendation will not be followed [30].
Stopping rule
The principle investigators reserved the right to discon-
tinue the study prior to inclusion of the intended num-
ber of subjects, but intends only to exercise this right for
valid scientific or administrative reasons such as; a nega-
tive advice for continuing the study by the DSMB; in
case of a percentage difference in the administration of
adjuvant systemic therapy of more than 5% between
both study arms; or disappointing accrual so that the
total enrolment of 1644 patients seems not feasible [30].
Final analysis
Per protocol and in the intention to treat population will be
used to analyse the primary and secondary endpoints after
5 and 10 years of follow-up. To evaluate the null hypoth-
esis, uncorrected chi-squared statistics will be used. In case
of censored data, chi-square test will be based on the
Kaplan-Meier estimator. Cox proportional hazards models
and Kaplan Meier estimates will be used to analyse the out-
come of both groups and to assess the univariable and
multivariable association between prognostic variables,
treatment and events, using stratification factors. All statis-
tical tests are 1-sided and a p value of 0.05 or less is consid-
ered statistically significant [30].
Discussion
The BOOG 2013-08 trial is a Dutch prospective non-in-
feriority randomized multicenter trial invesitgating
whether the sentinel lymph node biopsy can be safely
omitted in clincially node negative breast cancer patients
treated with breast conserving therpay. If the sentinel
lymph node biopsy can be safely omitted in clinically
node negative breast cancer patients undergoing breast
conserving therapy, this study will costeffectively lead to
a decreased axillary morbidity rate and thereby improved
quality of life with non-inferior regional control, distant-
disease free survival and overall survival.
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